A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified. The dual therapy — which combines the multikinase inhibitor drug regorafenib to ‘reprogram’ the tumor immune microenvironment, and programmed cell death 1 antibodies to stimulate anti-tumor immunity — improved survival in mouse models of HCC beyond what each therapy could have achieved alone.
